How to Test Human-Specific Combination Immunotherapies In Vivo
Por um escritor misterioso
Descrição
Learn how to evaluate combinations of human-specific checkpoint inhibitors in vivo, with double knock-in humanized drug target mouse models.
Targeting Tumor-Associated Antigens and Tumor-Specific Antigens
Nanotechnology-based products for cancer immunotherapy
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
CRISPR Clinical Trials: A 2021 Update - Innovative Genomics Institute (IGI)
Gemcitabine in the Era of Cancer Immunotherapy
Antibody–drug conjugates: in search of partners of choice: Trends in Cancer
Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV- specific CD8+ T cells in people living with HIV - eBioMedicine
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Mechanism of chemoradiation-immunotherapy combination in esophageal
Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity
Frontiers Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research
Inducing CAR-macrophages in the brain for local treatment
Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy
Pharmaceutics, Free Full-Text
de
por adulto (o preço varia de acordo com o tamanho do grupo)
